Company Quick10K Filing
Conformis
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 69 $267
10-Q 2019-11-01 Quarter: 2019-09-30
10-Q 2019-08-02 Quarter: 2019-06-30
10-Q 2019-05-03 Quarter: 2019-03-31
10-K 2019-03-13 Annual: 2018-12-31
10-Q 2018-11-05 Quarter: 2018-09-30
10-Q 2018-08-02 Quarter: 2018-06-30
10-Q 2018-05-04 Quarter: 2018-03-31
10-K 2018-03-09 Annual: 2017-12-31
10-Q 2017-11-09 Quarter: 2017-09-30
10-Q 2017-08-07 Quarter: 2017-06-30
10-Q 2017-05-10 Quarter: 2017-03-31
10-K 2017-03-08 Annual: 2016-12-31
10-Q 2016-11-10 Quarter: 2016-09-30
10-Q 2016-08-11 Quarter: 2016-06-30
10-Q 2016-05-13 Quarter: 2016-03-31
10-K 2016-03-24 Annual: 2015-12-31
10-Q 2015-11-09 Quarter: 2015-09-30
10-Q 2015-08-14 Quarter: 2015-06-30
8-K 2020-02-04 Officers, Exhibits
8-K 2020-01-14 Earnings, Exhibits
8-K 2019-12-17 Regulation FD
8-K 2019-12-05 Regulation FD
8-K 2019-10-30 Earnings, Exhibits
8-K 2019-10-18 Officers
8-K 2019-10-01 Officers, Exhibits
8-K 2019-09-30 Enter Agreement, M&A, Other Events, Exhibits
8-K 2019-07-31 Earnings, Exhibits
8-K 2019-06-25 Enter Agreement, Leave Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-05-01 Earnings, Exhibits
8-K 2019-04-29 Shareholder Vote
8-K 2019-04-22 Officers
8-K 2019-03-01 Other Events
8-K 2019-02-06 Earnings, Exhibits
8-K 2019-01-08 Earnings, Exhibits
8-K 2018-12-17 Enter Agreement
8-K 2018-12-13 Enter Agreement, Off-BS Arrangement, Other Events, Exhibits
8-K 2018-11-13
8-K 2018-10-31 Earnings, Exhibits
8-K 2018-09-14 Enter Agreement, Other Events, Exhibits
8-K 2018-09-04 Officers
8-K 2018-08-01 Earnings, Exhibits
8-K 2018-07-31 Officers, Regulation FD, Exhibits
8-K 2018-05-02 Earnings, Exhibits
8-K 2018-04-30 Shareholder Vote
8-K 2018-02-07 Earnings, Exhibits
8-K 2018-02-06 Officers, Exhibits
8-K 2018-01-25 Enter Agreement, Other Events, Exhibits
8-K 2018-01-24 Earnings, Regulation FD
8-K 2018-01-08 Earnings, Exhibits

Conformis Financials

CFMS Metrics, Comps, Filings

Annual | Quarterly

Business

We are a medical technology company that uses our proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, which we refer to as customized, to fit each patient's unique anatomy. The worldwide market for joint replacement products is approximately $18.1 billion annually and growing, and we believe our iFit technology platform is applicable to all major joints in this market. We offer a broad line of customized knee implants designed to restore the natural shape of a patient's knee. We have sold a total of more than 90,000 knee implants, including more than 70,000 total knee implants and 20,000 partial knee implants. In multiple clinical studies, iTotal CR, our cruciate-retaining total knee replacement implant and best-selling product, demonstrated superior clinical outcomes, including better function, including kinematics and objective functional measures, and greater patient satisfaction compared to those off-the-shelf implants that it was tested against. In March 2016, we initiated the broad commercial launch of the iTotal PS, our posterior-stabilized total knee replacement implant which addresses the largest segment of the knee replacement market. On July 31, 2018, our first Conformis Hip Systems were implanted. We are in limited commercial launch with the Conformis Hip System and intend to enter full commercial launch in the second half of 2019.

Our iFit technology platform comprises three key elements:

-iFit Design, our proprietary algorithms and computer software that we use to design customized implants and associated single-use, patient-specific instrumentation, which we refer to as iJigs, based on a computed tomography, or CT, scan of the patient and to prepare a surgical plan customized for the patient that we call iView.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Establishment Labs (ESTA) 424,433 59% -20.4 -28% 104,801 51,014 75,145 44,250 -29,027 -19,282 392,563
Park Ohio (PKOH) 387,624 16% 6.7 4% 1,324,300 994,100 1,655,600 264,800 49,600 140,500 937,624
Willis Lease Finance (WLFC) 348,508 80% 6.7 3% 1,930,783 1,560,774 395,730 318,397 65,641 232,513 1,567,302
Sientra (SIEN) 337,058 62% -2.2 -44% 245,945 130,772 73,974 45,621 -109,314 -102,131 229,709
Lawson Products (LAWS) 323,644 55% 20.5 3% 209,032 99,700 352,430 194,157 7,237 15,375 315,929
RTI Surgical (RTIX) 292,200 50% 22.5 -0% 361,186 111,336 280,855 140,123 -1,250 14,700 330,324
Conformis (CFMS) 266,514 55% -11.2 -49% 65,038 37,737 91,270 50,040 -31,651 -23,673 265,137
Northern Technologies International (NTIC) 230,357 32% 26.6 11% 66,155 9,816 57,047 18,491 6,976 8,475 225,132
Invacare (IVC) 162,405 27% 22.3 -5% 867,583 535,657 948,412 260,334 -39,874 13,756 306,329
Lakeland Industries (LAKE) 96,094 33% 26.2 -0% 101,385 17,800 101,206 33,222 -496 3,398 89,148
Shiloh Industries (SHLO) 93,757 8% 6.7 -2% 674,288 483,167 1,095,803 89,780 -14,751 49,220 328,521
Virco Manufacturing (VIRC) 66,783 35% 12.6 -0% 183,962 123,697 200,597 70,087 -717 9,335 117,654
Precision Therapeutics (AIPT) 47,456 68% 25.9 5% 32,252 9,960 1,183 801 1,465 1,831 47,386
Alpha Pro Tech (APT) 47,112 37% 7.1 12% 37,769 4,664 46,792 17,447 4,385 5,863 41,610
Hudson Technologies (HDSN) 36,221 10% -14.9 -18% 219,236 167,222 156,941 15,431 -39,823 -9,253 137,580
Rewalk Robotics (RWLK) 29,302 58% -0.7 -57% 31,972 14,704 4,721 2,737 -18,138 -18,136 12,304
Nanovibronix (NAOV) 24,150 64% -3.4 -204% 3,107 1,172 451 288 -6,327 -6,446 21,779
Milestone Scientific (MLSS) 17,427 58% -9.7 -30% 6,788 5,951 9,644 5,621 -2,007 -1,557 15,089
Myomo (MYO) 13,197 103% -0.6 -123% 8,543 1,436 2,289 2,362 -10,505 -10,505 6,453
Industrial Services of America (IDSA) 9,243 3% -105.6 -11% 26,893 17,649 58,357 1,777 -3,050 -162 17,101

Balance Sheet ($'000)2015-12-312016-12-312017-12-312018-12-31
Cash60065,500500500
Accounts Receivable14,86714,67513,20013,244
Inventory11,52011,7209,1849,534
PP&E10,96615,08416,51414,439
Assets159,369112,81093,79862,983
Accounts Payable4,7185,4744,8913,445
Long-Term Debt481030,00015,000
Liabilities18,15718,75547,28526,783
Stockholders' Equity141,21294,05546,51336,200
Income Statement ($'000)2015-12-312016-12-312017-12-312018-12-31
Revenue62,79178,92177,10089,789
Cost of Revenue42,41553,19249,30141,304
Gross Profit24,47226,70728,81448,485
R&D16,99716,60817,13616,869
SG&A63,43666,24367,52563,577
Tax1875216261
Net Income-57,246-57,588-53,580-43,365
Cash Flow ($'000)2015-12-312016-12-312017-12-312018-12-31
Cash Operating-54,450-49,132-37,856-26,982
Cash Investing-806-35,425-10,04115,626
Cash Financing134,5653,60232,6977,655